$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today

1/30/24 12:06:11 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EPIX alert in real time by email

ESSA Pharma (NASDAQ:EPIX) has outperformed the market over the past 5 years by 3.09% on an annualized basis producing an average annual return of 15.65%. Currently, ESSA Pharma has a market capitalization of $297.22 million.

Buying $1000 In EPIX: If an investor had bought $1000 of EPIX stock 5 years ago, it would be worth $2,060.30 today based on a price of $6.73 for EPIX at the time of writing.

ESSA Pharma's Performance Over Last 5 Years

comp_fig

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Get the next $EPIX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EPIX

Date	Price Target	Rating	Analyst
11/4/2024		Buy → Hold	Jefferies
11/4/2024		Outperform → Perform	Oppenheimer
11/4/2024	$15.00 → $2.00	Overweight → Neutral	Piper Sandler
6/26/2023	$17.00	Outperform	Oppenheimer
8/17/2021	$36.00 → $22.00	Outperform	Oppenheimer

More analyst ratings

$EPIX
Press Releases

Fastest customizable press release news feed in the world

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy data showed the single-agent enzalutamide control arm performing better than historical controls and similar to the combination of masofaniten and enzalutamide and therefore, unlikely to achieve the primary endpoint of the study Additional clinical studies with masofaniten including the combination study with abiraterone acetate and apalutamide as well as the remaining investigator sponsored trials will also
10/31/24 8:57:00 PM ET
$EPIX
Biotechnology: Pharmaceutical Preparations
Health Care
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD Across all dosing cohorts, 88% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL. After 15.2 months of follow up, median time to PSA progression and radiographic progression free survival have not yet been reached. SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 13, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pha
9/13/24 5:19:00 PM ET
$EPIX
Biotechnology: Pharmaceutical Preparations
Health Care
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 11, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 9:10 a.m. ET in New York, NY. David R. Parkinson, President and Chief Executive Officer, Peter Virsik, Chief Operating Officer and Executive Vice President, and David S. Wood, Chief Financial Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed in the Investors/Events
9/11/24 4:05:00 PM ET
$EPIX
Biotechnology: Pharmaceutical Preparations
Health Care

$EPIX
Financials

Live finance-specific insights

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024
On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in the first quarter of 2025, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations well beyond 2025 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 5, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the
8/5/24 7:00:00 AM ET
$EPIX
Biotechnology: Pharmaceutical Preparations
Health Care
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in 1Q25, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 14, 2024 /C
5/14/24 7:00:00 AM ET
$EPIX
Biotechnology: Pharmaceutical Preparations
Health Care
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in 1Q25, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 14, 2024 /P
5/14/24 7:00:00 AM ET
$EPIX
Biotechnology: Pharmaceutical Preparations
Health Care

$EPIX
Leadership Updates

Live Leadership Updates

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berg
3/7/24 8:13:00 PM ET
$EPIX
Biotechnology: Pharmaceutical Preparations
Health Care
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin
3/7/24 8:13:00 PM ET
$EPIX
Biotechnology: Pharmaceutical Preparations
Health Care
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios. "Lauren's cross-functional expertise in guiding products through all stages of commercial development adds a valuable perspective that complements the sk
6/6/23 7:00:00 AM ET
$EPIX
Biotechnology: Pharmaceutical Preparations
Health Care

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today

ESSA Pharma's Performance Over Last 5 Years

Chat with this insight

Recent Analyst Ratings for $EPIX

$EPIX Press Releases

Fastest customizable press release news feed in the world

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress

ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference

$EPIX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

$EPIX Market Insights

Live Market Insights

$EPIX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$EPIX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$EPIX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Oppenheimer Maintains Outperform on ESSA Pharma, Maintains $17 Price Target

ESSA Pharma: Q1 Earnings Insights